Gen QA

MEMBER LOGIN

MENU menu

Close close menu

Thyroid cancer

BACK TO EQA DIRECTORY

Testing for somatic small nucelotide variants in thryoid cancer.

EQA INFORMATION

EQA Code
TT
Submission
Clinical Report
Techniques
Next Generation Sequencing (NGS)
Eligibility
All laboratories worldwide. 
Language
English, French, German, Italian, Polish, Portuguese, Spanish
EQA Accreditation
EQA accredited to ISO 17043:2023
EQA open

20 October 2025

Testing period
6 weeks

OTHER INFORMATION

 What are participants required to do?
  • Enrolled participants will receive details by email when an EQA is open for assessment and/or samples have been dispatched.  
  • Participants are expected to access the instructions and information for the cases/samples online and to analyse them according to their laboratory/centre protocols. 
  • Participants must submit their anonymised results by the deadline using their standard laboratory report or a proforma provided by GenQA.  The submitted results are independently assessed for the accuracy of the analytical/genotyping results, clinical interpretation of the results (if appropriate) and clerical accuracy (including report layout and content). 

What can I expect as a participant?
Every participant will receive:
  • An Individual Laboratory/Centre Report (ILR/ICR) with educational advice for each distribution of this EQA.
  • The Summary report for each distribution of this EQA which contains information regarding general findings, a summary of methodologies used, common errors, number of participants and benchmarking. 
  • Access to a live Performance Certificate summarising your performance status for all EQAs in which you are enrolled.

Please note: EQA details may be subject to change prior to EQA distribution.   

PRODUCTS

Sample type: FFPE (Formalin Fixed Paraffin Embedded sections)
Testing/analysis: RET, BRAF, KRAS, NRAS, HRAS, TP53, KRAS, TERT promoter: small variant and fusion transcript analysis using Next Generation Sequencing.

Testing of all genes for this EQA is not compulsory.  Please test and report only the genes included in your routine laboratory scope.   
Conditions/Gene target(s):
  • Thyroid papillary carcinoma
  • Thyroid follicular carcinoma
  • Poorly differentiated anaplastic thyroid carcinoma
  • Thyroid medullary carcinoma
  • Phaeochromocytoma
  • Adrenal cortical carcinoma
Number of cases: Two or three

PURCHASE NOW

 

ASK A QUESTION

Thyroid cancer

Enter your details here: